Johnson & Johnson’s (NYSE: JNJ) stock price can trend higher and reach fresh highs repeatedly over the coming years because of its robust pipeline, including the recently approved OTTAVA surgical system. It is the first of its kind, a table-top integrated robotic device approved for limited but expanding use in the United States. Though it makes up a small portion of revenue today, it is central to the long-term outlook, which includes a slow acceleration to double-digit top-line growth and widening margins.
OTTAVA’s approval is a game-changer for JNJ, transforming it from a legacy medtech into a next-gen innovator capable of claiming share in high-growth markets. It places the company in direct competition with robotics leader Intuitive Surgical (NASDAQ: ISRG), shifting the growth engine to its MedTech segment even as the pharmaceutical segment is expected to sustain steady growth.
